反応式
[C:1]([N:8]1[CH:12]=[CH:11]N=C1)([N:3]1[CH:7]=[CH:6]N=C1)=[O:2].NC1C=[CH:29][C:17]([O:18][C:19]2[CH:24]=[CH:23][N:22]=[C:21]([C:25]([NH:27][CH3:28])=[O:26])[CH:20]=2)=[CH:16][C:15]=1[F:31].[CH3:32][N:33]1[C:41]2[C:36](=CC(N)=[CH:39][CH:40]=2)[CH:35]=[N:34]1>C1C=CC=CC=1.C(Cl)Cl>[F:31][C:15]1[CH:16]=[C:17]([CH:29]=[CH:11][C:12]=1[NH:8][C:1]([NH:3][C:7]1[CH:6]=[C:36]2[C:41](=[CH:40][CH:39]=1)[N:33]([CH3:32])[N:34]=[CH:35]2)=[O:2])[O:18][C:19]1[CH:24]=[CH:23][N:22]=[C:21]([C:25]([NH:27][CH3:28])=[O:26])[CH:20]=1参加物
反応物 3
生成物 1
試薬・触媒・溶媒 2
実験手順
To a solution of 1,1′-carbonyldiimidazole (62 mg, 0.38 mmol) in benzene (2 mL) and CH2Cl2 (1 mL) was added 4-(4-amino-3-fluorophenoxy)-N-methylpyridine-2-carboxamide (100 mg, 0.38 mmol). The resulting solution was stirred at room temperature for 16 h, then was treated with 1-methyl-5-aminoindazole (56 mg, 0.38 mmol). The reaction continued to stir at room temperature for 18 h. The mixture was concentrated under reduced pressure and the residue was triturated with Et2O. The solid was collected by filtration, and then purified by preparative HPLC to afford 44 mg (27%) of the title product. 1H-NMR (DMSO-d6) δ 2.78 (d, J=4.8, 3H), 4.01 (s, 3H), 7.02-7.07 (m, 1H), 7.14-7.18 (m, 1H), 7.28-7.36 (m, 2H), 7.39 (d, J=2.9, 1H), 7.52-7.59 (m, 1H), 7.89-7.96 (m, 2H), 8.23 (t, J=9.0, 1H), 8.49 (d, J=4.9, 1H), 8.57-8.63 (m, 1H), 8.71-8.81 (m, 1H), 9.06 (s, 1H); MS LC-MS [M+H]+=435.1; mp 231-234° C.
後処理
- stirringto stir at room temperature for 18 h
- concentrationThe mixture was concentrated under reduced pressure
- customthe residue was triturated with Et2O
- filtrationThe solid was collected by filtration
- custompurified by preparative HPLC
出典と根拠
- ORDレコード
- ord-42cb988f1dd64c1da18e768779d9d0bc
- 出典データセット
- uspto-grants-2011_12
- 特許番号
- US08076488B2
関連ノート
読み込み中…